The low-density-lipoprotein receptor-related protein 5 (LRP5), a coreceptor in the canonical Wnt signaling pathway, has been implicated in human disorders of low and high bone mass. Loss-of-function mutations cause the autosomal recessive osteoporosis-pseudoglioma syndrome, and heterozygous missense mutations in families segregating autosomal dominant high bone mass (HBM) phenotypes have been identified. We expressed seven different HBM-LRP5 missense mutations to delineate the mechanism by which they alter Wnt signaling. None of the mutations caused activation of the receptor in the absence of ligand. Each mutant receptor was able to reach the cell surface, albeit at differing amounts, and transduce exogenously supplied Wnt1 and Wnt3a signal. All HBM mutant proteins had reduced physical interaction with and reduced inhibition by DKK1. These data suggest that HBM mutant proteins can transit to the cell surface in sufficient quantity to transduce Wnt signal and that the likely mechanism for the HBM mutations' physiologic effects is via reduced affinity to and inhibition by DKK1.
Low-density-lipoprotein receptor-related protein 5 (LRP5) is a single-pass transmembrane protein that belongs to the low-density-lipoprotein receptor superfamily. One function of LRP5 is to serve as a coreceptor in the canonical Wnt signaling cascade (8) . Several in vitro observations support this function. For example, LRP5 transduced Wnt signal in cultured cells, and decoy forms of LRP5 could interfere with Wnt signaling (7) . Additionally, yeast two-hybrid experiments identified Axin, a cytoplasmic component of the canonical signaling cascade, as being an LRP5-interacting partner (24) . In vivo support for a role in Wnt signaling comes from studies of Xenopus laevis in which LRP5 was shown to synergize with Wnt to induce secondary axis formation (29) . Furthermore, two closely related homologs of LRP5, arrow in Drosophila melanogaster and LRP6 in vertebrates, have also been shown to transduce Wnt signal (29, 33) , and genetic interaction between LRP5 and LRP6, with respect to limb patterning, in mice has been observed (9, 18) .
For humans, two disorders affecting bone mass have been associated with mutations in LRP5. Loss-of-function mutations cause the autosomal recessive osteoporosis-pseudoglioma syndrome (OPPG) (7) . Individuals with this disease have skeletal fragility, due to low bone mass, and blindness, due to impaired blood vessel regression. The second skeletal phenotype associated with LRP5 mutation is autosomal dominant high bone mass (HBM), which is caused by heterozygous missense mutations ( Fig. 1) (4, 21, 32) . Affected individuals in families segregating HBM can develop complications associated with excessive bone formation, such as cranial nerve compression and severe headache (34) ; however, they have markedly reduced risks of skeletal fracture. OPPG and HBM phenotypes have been suggested to result from altered Wnt signaling (16) . Skeletal phenotypes have also been noted when other Wnt signaling components have been altered. Disruption of secreted Frizzled-related protein 1, a secreted Wnt antagonist, causes high bone mass in mice (3) . Increased production of DKK1, a canonical Wnt signaling inhibitor, by myeloma cells has been shown to correlate with bone lesions in patients with multiple myeloma (30) . Tissue-specific deletion of ␤-catenin in skeletal precursor cells in developing mice leads to complete failure of osteoblast differentiation (12) . Transgenic mice that overexpress Wnt10b in bone marrow mesenchymal progenitor cells have significantly increased bone mass, while Wnt10b null mice exhibit decreased bone mass (2) . Alterations in bone mass have also been observed in mice with osteoblast-specific deletions of ␤-catenin or Apc, with the former having low bone mass and the latter increased bone mass (10a). Additionally, reduced bone mass in mice having osteoblast-specific overexpression of Dkk-1 has been reported in abstract form (20a) . Finally, introduction of a single Lrp6 null allele onto a Lrp5 knockout background further reduced bone mineral density in mice (9) , suggesting that Lrp5 and Lrp6 have partially overlapping roles in determining bone mass.
The types of mutations that cause OPPG are consistent with this phenotype being due to loss of LRP5 function. Disease alleles commonly involve nonsense and frameshift mutations, and OPPG-associated missense mutations fail to transduce Wnt signal in cell culture assays (7; our unpublished data). However, not all LRP5 missense mutations negatively affect Wnt signaling, since seven different mutations in families segregating HBM phenotypes have been described. Only one HBM mutation (G171V) has been studied in vitro (4, 37) . When transiently transfected into cells, the G171V mutant LRP5 protein was not constitutively active and did not transduce Wnt signal at levels greater than the wild-type (WT) levels (4); however, the mutant LRP5 protein was less efficiently inhibited by an endogenous inhibitor of LRP5 signaling, DKK1 (4) . This led to the suggestion that the G171V-associated HBM phenotype was caused by reduced inhibition of LRP5 signaling during anabolic bone formation. More recently, a mechanism for reduced DKK1 inhibition was proposed when the G171V mutant was shown to transit poorly to the cell surface and not interact with the LRP5 intracellular chaperone MESD (37) . These results implied that the HBM phenotype was caused by autocrine, intracellular signaling between Wnt ligand and mutant LRP5 that is retained within the endoplasmic reticulum and is not accessible to extracellular DKK1.
Here we report functional studies that utilized seven different HBM-causing missense mutations (Fig. 1) , which we performed to determine how they affect Wnt signaling. We found that none of the HBM mutations were active in the absence of added Wnt. Even though different HBM mutant proteins transited the cell and reached the surface with differing efficiencies, all were able to transduce exogenously applied Wnt at levels comparable to those for WT-LRP5. However, compared to WT-LRP5, all of the HBM mutants were less inhibited by exogenously applied DKK1 protein and had reduced physical interaction with DKK1. We conclude that autocrine activation of Wnt signaling is not likely to be the general mechanism by which all missense mutations in LRP5 result in HBM phenotypes. Instead, our data support diminished regulation of the pathway by endogenous inhibitors, such as DKK1, as the most consistent mechanism for each of the HBM mutation's effects.
MATERIALS AND METHODS
Expression constructs for LRP5, MESD, and DKK1. Full-length human WT-LRP5, full-length human WT-LRP5 that has a myc epitope at the carboxy terminus (WT-LRP5-myc), and a truncated form of human WT-LRP5 that lacks the transmembrane and cytoplasmic domains but has a myc epitope at the carboxy terminus (WT-LRP5N-myc) were cloned into the pcDNA3.1 expression vector (Invitrogen) as previously described ( Fig. 1) (7) . Seven different HBMcausing missense mutations and one mutation (T173M) that has been associated with autosomal dominant familial exudative vitreoretinopathy (31) were individually introduced into a 1.3-kb EcoRI/SalI restriction fragment containing the first epidermal growth factor-like (EGF-like) domain by site-directed mutagenesis (Quikchange; Stratagene). After it was confirmed that only the expected mutation and no other alteration was present within the mutated 1.3-kb fragment, the FIG. 1. Schematic of LRP5 expression constructs and sites of HBM-associated missense mutations. (A) WT and high bone mass-associated mutant LRP5 protein expression constructs. Each construct contained either a WT sequence or a single HBM-associated mutation. Specific amino acid mutations (in single-letter code) and their relative locations within the first EGF-like domain of LRP5 are noted. Constructs were full-length, untagged LRP5, full-length LRP5 that was tagged at the carboxy terminus with a myc-epitope (LRP5-myc), truncated LRP5 protein lacking the transmembrane and cytoplasmic domains but tagged at the carboxy terminus with a myc-epitope (LRP5N-myc). (B) Locations of the HBM mutations modeled on the three-dimensional structure of the EGF-like domain of the low-density-lipoprotein receptor (14) by using the RasMol molecular graphics visualization tool (version 2.6, September 1996 update [http://www.umass.edu/microbio/rasmol/getras.htm]; R. Sayle, Stevanage, United Kingdom). Note that all mutations affect residues near the top surface (side view) and central region (top view) of the ␤-propeller structure within the EGF-like domain.
VOL. 25, 2005 FUNCTIONAL ANALYSES OF LRP5 HIGH-BONE-MASS MUTATIONS 4947 fragment was then shuttled into the LRP5, LRP5-myc, and LRP5N-myc expression vectors.
To generate the expression construct containing the entire extracellular domain of human LRP6 fused to the constant region of the mouse immunoglobulin G (IgG) heavy chain (LRP6N-Fc), the sequence encoding the entire human LRP6 extracellular domain was cloned into N-LRP6-mIgG (described in reference 10) to generate LRP6N-Fc. The G158V mutant of LRP6N-Fc, which is equivalent to G171V in LRP5, was generated by site-directed mutagenesis and sequence verified.
To generate a carboxy-terminal V5-tagged version of mouse Wnt1, the gene was PCR amplified from cDNA. The forward primer attached a HindIII restriction site, and the reverse primer eliminated the stop codon and inserted an EcoRI restriction site. The PCR product was cloned into the TOPO Blunt vector (Invitrogen) to generate TOPO-mWnt1. This vector was sequenced to verify the amplified product. The TOPO-mWnt1 vector was digested with HindIII and EcoRI, and the mWnt1 fragment was cloned into the pcDNA6-V5/His expression plasmid (Invitrogen) to generate mWnt1-V5.
Xi He provided a Flag-tagged human DKK1 construct (27) that we subcloned into pcDNA3.1. DKK1-V5 was made by PCR amplifying DKK1 cDNA and cloning it into the pcDNA3.1-V5/His expression vector (Invitrogen). Bernadette Holdener provided mouse MESD-C2 and RAP expression constructs (11) . Ormond MacDougald provided a mouse Wnt10b construct (2), which we subcloned into pcDNA3.1. Hans Clever provided the Topflash reporter construct (20) . A Renilla luciferase construct, pRL-TK, was purchased (Upstate Biotechnology).
Cell culture, expression of LRP5, LRP6, and DKK1, and collection of conditioned media. HEK293T cells and Cos7 cells (American Type Culture Collection) were cultured in Dulbecco's modified Eagle's medium (DMEM) (Cellgro) with 10% fetal bovine serum (FBS) (Gibco-BRL). Conditioned medium (CM) containing DKK1-Flag (DKK1-CM) and conditioned medium from empty-vector-transfected cells (pcDNA3-CM) were generated by transiently transfecting 80% confluent 293T cells in six-well plates by use of Lipofectamine Plus (Invitrogen), following the manufacturer's protocol. Twenty-four hours after transfection, the culture medium was changed to 1 ml serum-free DMEM. Conditioned medium was collected 24 h later and stored frozen at Ϫ80°C until use.
LRP5N-myc recombinant protein was expressed in Cos7 or 293T cells. Cells were plated at 2 ϫ 10 5 cells per well in six-well culture plates 24 h prior to transfection. Cos7 cells were transfected with 0.2 g each of LRP5N-myc, MESD-C2, and RAP expression vectors by use of FuGENE 6 (Roche) following the manufacturer's protocol, while 293T cells were transfected by use of Lipofectamine Plus. Twenty-four hours after transfection, the culture medium was changed to serum-free DMEM. Conditioned medium was then collected 24 h later. Two percent of conditioned media and 2% of cell lysate were analyzed by immunoblot following reducing SDS-PAGE.
Control Rat2 cells and Rat2 cells stably expressing Wnt1 were provided by Anthony Brown (6) . These cells were cultured in DMEM containing 10% FBS and Geneticin (50 g/ml). Control L cells and L cells stably expressing Wnt3a were obtained from the American Type Culture Collection. These cells were also cultured in DMEM containing 10% FBS and Geneticin (50 g/ml).
Biotinylation of cell surface protein and immunodetection of biotinylated LRP5. Cos7 cells were cultured in DMEM containing 10% FBS in 60-mm plates and, when 80% confluent, were transfected with 1.2 g full-length LRP5-myc and 0.8 g MESD-C2 expression vectors by use of the FuGENE 6, following the manufacturer's protocol. Forty-eight hours after transfection, cells were washed three times with ice-cold phosphate-buffered saline (PBS). Cells were incubated with PBS containing 0.5 mg/ml Sulfo-NHS-LC-Biotin (Pierce) at 4°C for 20 min. As a negative control, transfected cells were treated with PBS lacking the biotincross-linker at 4°C for 20 min. The labeling reaction was stopped by three washes of chilled PBS containing 50 mM NH 4 Cl at 4°C. Cells were lysed in 1 ml radioimmunoprecipitation assay (RIPA) buffer (50 mM Tris, pH 8, 150 mM NaCl, 1% NP-40, 0.5% deoxycholate, 0.1% sodium dodecyl sulfate). Biotinlabeled proteins were affinity purified from 0.4 ml cell lysate mixed with 0.5 ml RIPA buffer by use of 50 l streptavidin beads (Pierce). Samples were then resuspended in 40 l 2ϫ SDS-PAGE loading buffer, and 20 l was resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) under reducing conditions (5% ␤-mercaptoethanol [BME]). Following transfer onto polyvinylidene difluoride (PVDF) membrane, LRP5-myc was immunodetected by use of a monoclonal anti-myc antibody, 9E10 (Santa Cruz Biotechnology, Inc.). As a positive control for cell surface biotinylation, ␤1 integrin was immunodetected by using a monoclonal antibody MAB2252Z (Chemicon). Secondary antibody was horseradish peroxidase (HRP)-conjugated anti-mouse IgG. Immunopositive bands were visualized by chemiluminescence using the ECL-Plus Western detection system (Amersham).
Luciferase reporter assays for canonical Wnt signaling and immunodetection of LRP5 protein.
Each experiment was performed in triplicate and was repeated independently on at least three separate occasions. Assays involving 293T cells cotransfected with LRP5 and Wnt1-V5 or Wnt10b. 293T cells were plated at 2.5 ϫ 10 5 cells/well in 24-well plates 24 h prior to transfection. Cells were transfected by use of Lipofectamine Plus with Topflash reporter construct (100 ng), pRL-TK (5 ng), MESD-C2 (20 ng), Wnt1-V5 (100 ng) or Wnt10b (100 ng), and full-length, untagged LRP5 (20 ng) expression vectors in 250 l serum-free medium according to the manufacturer's protocol. As needed, empty pcDNA3.1 vector was added to make the total transfected DNA amount 250 ng. Four hours later, an additional 250 l of DMEM containing 20% FBS was added to the cells. When DKK1-Flag was added as an exogenous inhibitor in this assay, 100 l DKK1-CM or 100 l pcDNA3-CM was mixed with DMEM and FBS (to make a total volume of 250 ml containing 20% FBS) and added to each well 4 h after transfection. Cells were harvested 24 h later for determination of protein expression and luciferase activity.
Assays involving 293T cells transfected with LRP5 and cultured in Wnt3a-containing conditioned medium. A transfection protocol identical to the one described above was employed, except that no Wnt1-V5 construct was included among the transfected DNAs. Serum was added back to the cells 4 h after transfection. Twenty-four hours after transfection, culture medium was replaced by 100 l of Wnt3a-CM or control L cell-CM, along with 300 l of DMEM containing 10% FBS. When DKK1-Flag was added as an exogenous inhibitor in this assay, 70 l DKK1-CM or 70 l pcDNA3-CM was mixed with Wnt3a-CM or L cell-CM, DMEM, and FBS (to make a total volume of 400 l containing 10% FBS) and added to each well 24 h after transfection. Cells were harvested 24 h later for the determination of protein expression and luciferase activity. control or Wnt1-expressing Rat2 cells (to make a total volume of 400 l containing 10% FBS) and added to each well 24 h after transfection. Cells were harvested 24 h later for determination of protein expression and luciferase activity.
Measurement of luciferase activity. Cells were lysed in 100 l passive lysis buffer (Promega) and firefly (Topflash) luciferase activity and Renilla luciferase activity were measured using the dual luciferase assay kit (Promega) in a luminometer (Molecular Devices) following the manufacturers' instructions. Renilla luciferase activity served as an internal control for transfection efficiency.
Immunodetection of full-length, untagged LRP5. Twenty microliters of cell lysate from 100 l of passive lysis buffer was mixed with 5 l of 5ϫ SDS-PAGE loading buffer. Protein was resolved by SDS-PAGE under reducing conditions (5% BME), transferred to PVDF, and immunodetected by using a monoclonal anti-LRP5/LRP6 antibody 3801-100 (BioVision). As a positive control for equal cell lysate loading, immunodetection of tubulin was performed using monoclonal antibody D-10-HRP (Santa Cruz Biotechnology, Inc.).
Coimmunoprecipitation (co-IP) of LRP5 with MESD, LRP5 with DKK1-Flag, and LRP6 with DKK1-V5. 293T cells in 60-mm culture dishes were cotransfected with 0.5 g LRP5-myc and 0.5 g MESD-C2 expression vectors by use of Lipofectamine Plus. As control, 0.5 g empty pcDNA3.1 plasmid, instead of MESD-C2, was cotransfected with LRP5-myc. Cells were lysed in 1.5 ml RIPA buffer 48 h later. Lysates were freeze-thawed once before coimmunoprecipitation was performed. A total of 0.5 ml of lysate was subjected to immunoprecipitation by the addition of 10 l of the monoclonal anti-Flag antibody M2 (Sigma) and 50 l protein G Sepharose beads (Amersham) and rocking at 4°C for 2 h. The beads were then washed three times in high-stringency buffer (50 mM Tris, pH 8, 150 mM NaCl, 0.5% NP-40, 0.5% Triton X-100, 0.5 mM CaCl 2 , 0.5 mM MgCl 2 ) for 1 min each at 4°C and then pelleted and resuspended in 50 l of 2ϫ SDS-PAGE loading buffer containing 5% BME. Twenty microliters was then resolved by SDS-PAGE. Following transfer to PVDF, LRP5 protein was immunodetected by use of anti-myc monoclonal antibody 9E10, and MESD-C2 protein was immunodetected by use of anti-Flag antibody M2. Immunoprecipitation was also performed on 0.5 ml of lysate by adding 90 l of the anti-myc antibodyconjugated agarose beads (9E10 AC) (Santa Cruz Biotechnology, Inc.) and rocking at 4°C for 2 h. Washes, sample electrophoresis, and immunodetection were performed as previously detailed.
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For coimmunoprecipitation of LRP5N-myc and DKK1-Flag, conditioned medium containing LRP5N-myc was mixed with conditioned medium containing DKK1-Flag. Since HBM-LRP5 proteins were secreted into conditioned medium at various levels, immunodetection of secreted LRP5N-myc was first performed so that the amount of conditioned medium added for the co-IP experiments could be adjusted to provide equivalent amounts of secreted LRP5N-myc. This was accomplished by diluting aliquots of conditioned media containing the different LRP5N-myc proteins in serum free-media to a final volume of 1 ml. Fifty microliters of DKK1-Flag-containing conditioned medium was then added to the 1 ml of LRP5N-myc-containing medium, along with 10 l of the goat anti-myc polyclonal antibody c-Myc(A-14)-G (Santa Cruz Biotechnology, Inc.) and 50 l of protein G Sepharose beads (Amersham). Samples were rocked at 4°C for 5 h. Beads were then washed three times in low-stringency buffer (20 mM Tris, pH 7.5, 150 mM NaCl, 0.05% Tween 20) for 30 s each at 4°C and then pelleted and resuspended in 50 l of 2ϫ SDS-PAGE loading buffer containing 5% BME. Twenty microliters was then resolved by SDS-PAGE. Following transfer to PVDF, LRP5 protein was immunodetected by using anti-myc monoclonal antibody 9E10, and DKK1-Flag protein was immunodetected by using anti-Flag antibody M2.
For coimmunoprecipitation of LRP6N-Fc and DKK1-V5, conditioned medium containing LRP6N-Fc was mixed with conditioned medium containing DKK1-V5. LRP6N-Fc-and DKK1-V5-conditioned media were made by transiently transfecting 293T cells at 80% confluence in six-well plates with 0.8 g LRP6N-Fc and 0.2 g MESD-C2 expression vectors or with 1 g DKK1-V5 expression vector, respectively, using Lipofectamine Plus. Recombinant protein in 1 ml of serum-free medium was collected 48 h later. Immunodetection of secreted LRP6N-Fc was first performed so that the amount of conditioned medium added to the mixtures in the co-IP experiments could be adjusted to provide equivalent amounts of secreted LRP6N-Fc in 1 ml of serum-free DMEM. Fifty microliters of conditioned medium containing DKK1-V5 and 50 l of anti-mouse IgG agarose beads (Sigma) were then added. Samples were incubated at 4°C for 2 h with agitation. Beads were then washed four times in low-stringency buffer (20 mM Tris, pH 7.5, 150 mM NaCl, 0.05% Tween 20) for 1 min each at room temperature and then pelleted and resuspended in 50 l of 2ϫ SDS-PAGE loading buffer containing 5% BME. Twenty microliters was then resolved by SDS-PAGE. DKK1-V5 was immunodetected by using a horseradish peroxidase-conjugated monoclonal antibody against the V5 tag (Invitrogen); LRP6N-Fc was detected by using goat anti-mouse IgG antibody (Pierce). DKK1-V5 was used in these experiments instead of DKK1-Flag because the secondary antibody used to detect DKK1-Flag cross-reacted with an identically sized IgG fragment derived from the anti-mouse IgG agarose beads, making it difficult to determine whether DKK1-Flag had coprecipitated. This was not a problem when HRP-conjugated anti-V5 antibody was used.
RESULTS
HBM missense mutant LRP5 proteins are able to reach the cell surface. It has previously been reported that the chaperones MESD and RAP facilitate LRP5 and LRP6 processing and targeting to the cell membrane (11) . It has also been reported that the G171V HBM mutation has reduced affinity for MESD and reaches the cell surface less efficiently than wild-type protein (37) . We determined the abilities of seven different HBM mutants, including G171V, to reach the cell surface. We used two approaches to evaluate LRP5 trafficking. First, we expressed a truncated LRP5 protein that lacks the transmembrane and cytoplasmic domains and is tagged with a myc epitope at the carboxy terminus (LRP5N-myc). When coexpressed with MESD, WT-LRP5N-myc was efficiently synthesized and secreted from Cos7 and 293T cells ( Fig. 2A and  B) . When trafficked normally, WT-LRP5 (and LRP6) protein that is secreted into the culture medium is glycosylated (11) and therefore migrates on SDS-PAGE at a slightly higher molecular weight than LRP5 protein recovered from cell lysate ( Fig. 2A) . All HBM mutants were capable of being posttranslationally modified and secreted by Cos7 and 293T cells, albeit at differing efficiencies ( Fig. 2A and B) . For example, the HBM mutant proteins (D111Y, A214T, A214V, and T253I) were present in the conditioned media at levels comparable to those for WT protein, while the mutants G171R, G171V, and A242T were present in the media at significantly reduced levels ( Fig.  2A and B) . Importantly, the last three mutants still migrated at the larger molecular weight, indicating that they had undergone posttranslational processing prior to being secreted. Second, we expressed full-length LRP5 protein containing the transmembrane and cytoplasmic domains, again, tagged with a carboxy-terminal myc epitope, and determined their abilities to traffic to the cell surface by biotinylating cell surface proteins (Fig. 2C) . The abundance of mutant protein at the cell surface (Fig. 2C ) correlated with abundance of the truncated (LRP5N-myc) protein in the conditioned media ( Fig. 2A and B) . This result indicates that the trafficking of many HBM mutants is similar to that of WT protein and implies that abnormal trafficking and autocrine intracellular signaling do not constitute a universal mechanism for altered Wnt signaling in HBM mutations.
Because MESD is required for posttranslational modification of LRP5 and each of the HBM-LRP5 mutants appeared to be posttranslationally modified similarly to WT-LRP5, we tested the affinity between MESD and the HBM mutant proteins by coimmunoprecipitation (Fig. 3) . Tagged versions of LRP5 and MESD were coexpressed in 293T cells and immunoprecipitation experiments were performed in each direction following disruption of the membranes at moderate stringency. All LRP5 mutants coprecipitated with MESD (Fig. 3) ; however, the affinities between the mutant forms of LRP5 and MESD did not correlate with their abilities to reach the cell surface (compare Fig. 2 and 3 ). For example, A242T was poorly targeted to the cell surface ( Fig. 2) but had a strong affinity for MESD in this assay (Fig. 3) . Conversely, A214T and T253I were efficiently trafficked ( Fig. 2) but had weak affinities for MESD (Fig. 3) . As previously reported (37), we found a decreased interaction between MESD and the G171V mutant.
HBM proteins with missense mutations were not constitutively active and were able to transduce Wnt signal at rates comparable to that of WT-LRP5. Since each of the HBM mutants reached the cell surface in different amounts and had different affinities for MESD, we tested whether they had altered abilities to transduce canonical Wnt signaling. We chose three different Wnt ligands that have previously been shown to activate canonical Wnt signaling, one of which has been implicated in the regulation of bone mass by use of transgenic and knockout mice (2) . However, we do not know which, if any, of these ligands is an endogenous inducer of LRP5-mediated signaling. We assessed Wnt activation of LRP5 by transfecting the Topflash and Renilla-luciferase reporter constructs along with untagged, full-length WT-LRP5 or HBM-LRP5 into 293T cells that were either (i) also cotransfected Wnt1-V5 or Wnt10b, (ii) subsequently cocultured with a Rat2 cell line that stably expressed Wnt1, or (iii) subsequently cultured in medium containing Wnt3a. In the absence of Wnt, neither WT-LRP5 nor any of the HBM-LRP5 mutants was constitutively active (Fig. 4A) . In all four signaling assays (i.e., cotransfection with Wnt1-V5 or Wnt10b, coculture with Wnt1 expressing cells, and addition of Wnt3a to the medium), each of the HBM mutants transduced Wnt signal at levels comparable to that for WT-LRP5 (Fig. 4A to D) . For example, coexpression of Wnt1-V5 and WT-LRP5 caused a 35-fold increase in luciferase VOL. 25, 2005 FUNCTIONAL ANALYSES OF LRP5 HIGH-BONE-MASS MUTATIONSactivity, whereas 35-fold to 47-fold increases were observed for the HBM-LRP5 mutants (Fig. 4A) . When LRP5-transfected cells were cocultured with Wnt1-expressing Rat2 cells, WT-LRP5 yielded an 11-fold increase in luciferase activity, and the HBM-LRP5 mutants yielded 10-fold to 15-fold increases (Fig.  4B) . These results imply that HBM mutant proteins, including those that inefficiently transited through the cell, were still able to reach the cell surface in sufficient quantity to transduce Wnt signal comparably to WT-LRP5. Wnt1, Wnt10b, and Wnt3a were able to activate canonical signaling in 293T cells that had not been transfected with LRP5 ( Fig. 4A to D) . This activation may be attributable to endogenous LRP5 and LRP6 receptors (23) . Although the number of endogenous receptors on 293T cells has not been determined, their quantity in NIH 3T3 cells has been estimated to be between 10 3 and 10 4 per cell (1). The anti-LRP5/LRP6 antibody we utilized could not detect the endogenous LRP5 or LRP6 receptors on 293T cells (Fig. 4E, first column) . Therefore, the amount of recombinant LRP5 protein expressed by transfected 293T cells (Fig. 4E) likely far exceeds the amount needed to efficiently transduce Wnt signal.
The patterns of response for the seven different HBM mutants, as assessed by induction (n-fold) of luciferase activity, are similar when Wnt10b and Wnt1 were transfected (compare Fig. 4D and A) . This response is not solely due to transfection, since the pattern of response to exogenously added Wnt1 was similar to that of transfected Wnt1 (compare Fig. 4B and A) . Interestingly, the pattern of HBM mutants' response to Wnt3a differed from that of Wnt1 or Wnt10b (compare Fig. 4C and A,  B, and D) . However, the Wnt3a pattern was the same whether the ligand was added exogenously or by transfection (data not shown). This result suggests that HBM mutations may cause subtle alterations in the affinities of the receptor for specific Wnt ligands.
All HBM-LRP5 mutants were less inhibited by DKK1 than WT-LRP5. It has previously been reported that the G171V-LRP5 mutant was less efficiently inhibited by DKK1 compared with WT-LRP5 (4). However, subsequent experiments demonstrated reduced trafficking of the G171V mutant to the cell surface and suggested that the reduced inhibition by DKK1 simply reflected there being less receptor at the cell surface; this result also suggested that the increased activity of the G171V mutant receptor was due to an intracellular interaction between the receptor and autocrine-produced Wnt ligand (37) . We tested this hypothesis by adding Wnt ligand exogenously to LRP5-transfected 293T cells. All HBM mutant receptors, including G171V, were able to respond to exogenously supplied Wnt1 and Wnt3a (Fig. 4B and C) , arguing against intracellular autocrine signaling as the likely mechanism. Also, as noted earlier, the patterns of responsiveness of the HBM mutants were the same whether Wnt1 was provided by cotransfection or by coculture (compare Fig. 4A and B) .
Importantly, for all three Wnt ligands, we observed that each HBM mutant was less efficiently inhibited by exogenously added DKK1 in these assays than was WT-LRP5 (Fig. 4A to  D) . When cells were cotransfected with Wnt1-V5, the induction of luciferase activity was 70% inhibited by adding DKK1 to cells expressing WT-LRP5, whereas none of the seven HBM-LRP5 mutants was inhibited by more than 30% (Fig.  4A) . Similar results were obtained when LRP5-transfected 293T cells were cocultured with Wnt1-expressing Rat2 cells. Exogenous DKK1 inhibited the induction of luciferase activity by 50% in cells expressing WT-LRP5 and by no more than 20% in any of the seven HBM mutant-expressing cells (Fig.  4B) . Although the induction in luciferase activity in cells treated with Wnt3a-containing conditioned medium was smaller than that in cells treated with Wnt1-containing medium, cells expressing WT-LRP5 were more effectively inhibited by DKK1 than cells expressing any of the seven HBM mutants (Fig. 4C) . The decreased inhibition by DKK1 in the HBM mutants was more clearly seen when Wnt10b was used as ligand ( Fig. 4D) , yielding results similar to those observed with the Wnt1 assays.
HBM-LRP5 mutants had lower affinities to DKK1 than WT-LRP5. DKK1 has previously been shown to physically interact with LRP5 and LRP6 (1, 27) , leading us to hypothesize that HBM mutants have reduced interaction with DKK1. We tested this hypothesis by performing coimmunoprecipitation experiments between LRP5 and DKK1 (Fig. 5A) . Human Flag-tagged DKK1 was expressed in 293T cells, and conditioned medium was mixed with conditioned medium containing secreted WT-LRP5N-myc or HBM-LRP5N-myc. For a control, we used LRP5 protein with the mutation T173M that had been identified in a patient with familial exudative vitreoretinopathy (31) . Like each of the HBM mutants, this mutant is within the first EGF-like repeat domain, but it does not affect Wnt1 or Wnt10b signaling in Topflash reporter assays (our unpublished data). As shown in Fig. 5A , wild-type LRP5N-myc as well as the control T173M-LRP5N-myc comparably interacted with DKK1 protein, whereas all seven HBM-associated mutant proteins had significantly reduced interactions.
Since LRP6, a close homolog of LRP5, also directly interacts with DKK1 (23), we created a G158V allele in LRP6N-Fc, which is equivalent in amino acid residue location to the G171V allele of LRP5. In contrast to WT-LPR6N-Fc, the G158V mutant did not coprecipitate DKK1 (Fig. 5B) .
DISCUSSION
Our data support a role for LRP5 in transducing Wnt signal, since all HBM mutations retained this functional property, while OPPG-causing mutations did not (our unpublished data). That each HBM mutation remains Wnt responsive is important, since recent data indicate that LRP5 can participate in other biologic pathways (5, 19, 22, 35) . In the eye, LRP5 likely acts as a coreceptor with Frizzled 4 for the ligand Norrin, since mutations in LRP5, FRZ4, and Norrin have each been associated with hereditary eye diseases that have altered growth and/or regression of the vitreal vasculature as a component feature (7, 15, 17, 31, 35 ). While it is formally possible that Norrin or an as yet unidentified protein could be the principal ligand for LRP5 in bone, several lines of evidence argue against this hypothesis. Low bone mass in humans with Norrie disease, who lack Norrin (28), has not been reported, whereas it has been reported for humans and mice lacking LRP5 (7, 9, 17) . Second, independent experiments involving modulation of different Wnt signaling pathway participants in mice have yielded effects upon bone mass (see, e.g., references 2, 3, and 10a). The clustering of all HBM mutations within the first EGFlike repeat domain of the receptor implied that the mutations would share a common mechanism by which they affected signaling. Our data for six new HBM-LRP5 mutants agree with prior data for the G171V mutant (4) and indicate that this mechanism does not involve constitutive activation in the absence of ligand. This distinguishes HBM-LRP5 missense mutations from mutations in other receptors, such as PTHRP, which have been found to cause Jansen metaphyseal dysplasia as the result of constitutive activation (25, 26) . We also show that all HBM-LRP5 mutants were able to transduce Wnt signal in the presence of added Wnt1 or Wnt3a. This is important because the Wnt interaction domain of LRP6 (and by extrapolation LRP5) is thought to involve the first and second EGFlike domains (23) , and OPPG-causing missense mutations in these domains destroy the receptor's ability to transduce Wnt signal (our unpublished data). Intriguingly, we observed that several HBM-LRP5 mutants, including G171V, had greater Wnt1 and Wnt10b responsiveness than WT-LRP5 but had slightly lower Wnt3a responsiveness (Fig. 4) . Consequently, it is possible that altering the affinity of the receptor to specific Wnt ligands in bone contributes to the high-bone-mass phenotype. Altered affinity of the fibroblast growth factor receptor 2 for fibroblast growth factor ligands has been implicated in causing Apert syndrome (13, 36) . Other investigators did not find increased Wnt1 signal transduction by the G171V mutation compared to that of the wild type when carboxy-terminal hemagglutinin-tagged LRP5 receptors were expressed (37); however, tagging the carboxy terminus may reduce maximal signaling, since we found a carboxy-terminal myc tag impaired signaling by 50% compared to untagged receptor (our unpublished data). Therefore, the complexity of the Wnt-Frizzled-LRP signaling pathway(s) (19 different Wnt ligands, 10 different Frizzled receptors, and LRP5 and LRP6) will likely require in vivo studies using knock-in and conditional knockout alleles, rather than in vitro studies, to ultimately dissect the pathway and thereby test the validity of altered affinity to specific Wnt ligands as the mechanism for HBM-LRP5 effects. Our results do not support the hypothesis that impaired processing of the G171V mutant and autocrine, intracellular signaling cause the HBM phenotype (37) . We found that all HBM-LRP5 mutants responded similarly to Wnt1 provided either by coculture or by cotransfection (Fig. 4A and B) . We also found that several HBM-LRP5s were able to transit to the cell surface (Fig. 2C) and had affinities to MESD that were similar to that of WT-LRP5 (Fig. 3) . When Wnt was added to cells that had not been cotransfected with LRP5, significant canonical signaling still occurred (Fig. 4A to D) , implying that endogenous LRP5 and/or LRP6 receptors transduced Wnt signal, even though they were not detectable on a Western blot (Fig. 4E) . Also, the inductions (n-fold) of Wnt signaling were similar, whether 5 ng, 50 ng, or 100 ng of LRP5 expression constructs was transfected (our unpublished data). This suggests that components other than the transfected LRP5 receptors are rate limiting. Taken together, our results suggest that all transfected HBM-LRP5 mutants reached the cell surface in amounts sufficient to maximally transduce Wnt signal. Our results also demonstrate that the choice of Wnt ligand is important when interpreting in vitro studies of LRP5 signaling. Zhang et al. (37) attributed the difference in responsiveness between the G171V mutant and WT LRP5 to added Wnt3a, as opposed to cotransfected Wnt1, to there being less G171V mutant receptor reaching the cell surface. However, we found that exogenous Wnt3a was a less potent activator and exogenous Wnt1 was a more potent activator of several HBM mutants, independent of their efficiencies in reaching the cell surface ( Fig. 4B and C) .
We suggest that the reduced inhibition by DKK1 provides the most parsimonious explanation for the mechanism by which HBM-LRP5 mutations have their effects. Each HBM mutant was less inhibited by DKK1 than WT, whether stimulated by Wnt1 delivered by cotransfection or coculture (Fig. 4A  and B) , by cotransfected Wnt10b (Fig. 4D) , or by Wnt3a added to the culture medium (Fig. 4C) . We noticed that when Wnt3a was used, exogenous DKK1 inhibited HBM-LRP5 more efficiently than when exogenous Wnt1 was used (compare Fig. 4C and B). This result suggests the involvement of other factors at the cell surface (e.g., Kremens, Frizzled coreceptors, or as yet unidentified proteins) during inhibition of LRP5 by DKK1 when different Wnt ligands are present.
Our results demonstrate that in comparison to WT-LRP5, all mutant HBM-LRP5 proteins have reduced affinities to DKK1. When one HBM mutation, G171V, was introduced into an equivalent location in LRP6 (G158V), it also impaired the interaction between LRP6 and DKK1 (Fig. 5B ). When first identified as an inhibitor of canonical Wnt signaling, DKK1 had been found to strongly interact with the third and fourth, but not the first and second, EGF-like domains of LRP6 (23). Note that WT-LRP6N-Fc was able to precipitate DKK1, whereas G158V-LRP6N-Fc was not.
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For LRP5, the first two EGF-like domains or the last two domains can bind DKK1 (37) . However, Wnt signaling through LRP5 protein that lacks the third and fourth domains or just the third domain could not be inhibited by DKK1, suggesting that DKK1 binding to the third propeller domain of LRP5 is critical for regulating canonical signaling (37) . While our studies have not addressed the requirement of the third domain, we clearly show that perturbation within the first domain of LRP5 or LRP6 can interfere with DKK1 binding. DKK2 has also been shown to inhibit canonical Wnt signaling by binding LRP6 (23) , and two other DKK family members are present in the human genome. Our results do not exclude the possibility that the HBM phenotype results from reduced inhibition by DKKs other than DKK1 or by other as yet unidentified extracellular inhibitors of LRP5. The existence of a naturally occurring allelic series of mutations within LRP5 that caused HBM phenotypes enabled us to mutate the specific disease-associated residues and evaluate their effects upon the Wnt signaling cascade. We found that mutations at these residues consistently interfered with inhibition of the receptor by DKK1, but not with activation of the receptor by Wnt ligand, trafficking of mutant receptor to the cell surface, or interaction of the mutant receptor with intracellular chaperones. Understanding precisely how missense mutations in the first EGF-like domain impair DKK1-mediated inhibition may lead to the rational design of pharmacologic inhibitors of this pathway that can be used to effect increases in bone mass among individuals with wild-type LRP5 receptors.
